Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability.
Opioids are the cornerstone medication for the treatment of moderate to severe pain. However, analgesic opioid requirements and the propensity to suffer from aversive opioid effects, including fatal respiratory depression and addiction, vary widely among patients. The factors underlying the substantial response variance remain largely unknown and need clarification for using opioids more effectively in appropriately selected patients. This ongoing study takes advantage of the twin paradigm to estimate the genetic and environmental contributions to inter-individual differences in opioid responses. Evidence of significant heritability will justify more detailed and extensive genomic studies. The enrollment target is 80 monozygotic and 45 dizygotic twin pairs who undergo a target-controlled infusion of the opioid alfentanil and saline placebo in sequential but randomized order. In a laboratory-type setting, well-defined pharmacodynamic endpoints are measured to quantify pain sensitivity, analgesic opioid effects, and aversive opioid effects including respiratory depression, sedation and reinforcing affective responses. First results obtained in 159 participants provide evidence for the feasibility and utility of this interventional study paradigm to estimate familial aggregation and heritability components of relevant drug effects. Areas highlighted in this report include recruitment strategies, required infrastructure and personnel, selection of relevant outcome measures, drug infusion algorithm minimizing pharmacokinetic variability, and considerations for optimizing data quality and quantity without hampering feasibility. Applying the twin paradigm to complex and potentially harmful studies comprehensively characterizing pharmacological response profiles is without much precedent. Methods and first results including heritability estimates for heat and cold pain sensitivity should be of interest to investigators considering similar studies.
Angst
Martin S
MS
Department of Anesthesia, Stanford University School of Medicine, CA, USA. ang@stanford.edu
Phillips
Nicholas G
NG
Drover
David R
DR
Tingle
Martha
M
Galinkin
Jeffrey L
JL
Christians
Uwe
U
Swan
Gary E
GE
Lazzeroni
Laura C
LC
Clark
J David
JD
D000328:Adult; D015760:Alfentanil / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D010147:Pain Measurement; D058748:Pain Perception; D010597:Pharmacogenetics / Q000379:methods*; D014429:Twins, Dizygotic / Q000235:genetics* / Q000378:metabolism*; D014430:Twins, Monozygotic / Q000235:genetics* / Q000378:metabolism*; D055815:Young Adult
D000701:Analgesics, Opioid; D015760:Alfentanil